US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Apogee Therapeutics

News headline image
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics to Participate in Upcoming June Conferences
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics to Participate in Upcoming March Conferences
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics to Participate in Upcoming Conferences
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE
News headline image
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
From Apogee Therapeutics
Via GlobeNewswire
Tickers APGE